tiprankstipranks
Neogen Chemicals Ltd. (IN:NEOGEN)
:NEOGEN
India Market
Want to see IN:NEOGEN full AI Analyst Report?

Neogen Chemicals Ltd. (NEOGEN) AI Stock Analysis

3 Followers

Top Page

IN:NEOGEN

Neogen Chemicals Ltd.

(NEOGEN)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 5.2)
Rating:52Neutral
Price Target:
₹1,718.00
▲(48.50% Upside)
Action:Reiterated
Date:05/21/26
The score is held back primarily by weakened financial quality—margin compression, sharply higher leverage, and negative operating/free cash flow—raising execution and funding risk. Technicals are supportive with the stock trading above major moving averages, but valuation remains a headwind due to the very high P/E, only modestly offset by the dividend yield.
Positive Factors
Multi-year revenue growth
Sustained top-line expansion from ~3.36B to ~8.62B over several years indicates expanding market adoption and scale in specialty intermediates. Durable revenue growth supports capacity utilization, supplier negotiating power, and long-term investment in product development and certifications.
Negative Factors
Sharp rise in leverage
A large increase in total debt and debt-to-equity to ~1.71 materially reduces financial flexibility. Higher leverage raises interest and refinancing risk, constrains strategic optionality, and magnifies downside during cyclical weak demand, making execution and funding more fragile over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth
Sustained top-line expansion from ~3.36B to ~8.62B over several years indicates expanding market adoption and scale in specialty intermediates. Durable revenue growth supports capacity utilization, supplier negotiating power, and long-term investment in product development and certifications.
Read all positive factors

Neogen Chemicals Ltd. (NEOGEN) vs. iShares MSCI India ETF (INDA)

Neogen Chemicals Ltd. Business Overview & Revenue Model

Company Description
Neogen Chemicals Limited manufactures and sells specialty chemicals in India. It offers organo bromine compounds, such as alkyl bromide compounds, dibromoalkane compounds, bromo chloro alkanes, bromine derivatives of organoacids, bromoacid ester c...
How the Company Makes Money
Neogen makes money primarily by manufacturing and selling specialty chemical products and intermediates, with revenue recognized from customer orders/contracts for these materials. Key revenue streams typically include: (1) Bromine-based specialty...

Neogen Chemicals Ltd. Financial Statement Overview

Summary
Despite strong multi-year revenue growth, the latest year shows clear deterioration: gross margin compressed (~32% vs ~46% prior year), net margin fell (~3.3%), leverage rose sharply (debt-to-equity ~1.71), and cash generation weakened materially with negative operating cash flow (~-3.37B) and deeply negative free cash flow (~-8.93B).
Income Statement
56
Neutral
Balance Sheet
38
Negative
Cash Flow
24
Negative
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue8.00B8.62B7.78B6.91B6.86B4.87B
Gross Profit3.69B2.78B3.54B1.42B2.98B1.40B
EBITDA1.37B1.37B1.36B1.13B1.16B865.60M
Net Income260.50M287.50M348.30M356.50M499.70M446.30M
Balance Sheet
Total Assets23.02B29.02B17.47B14.61B10.54B7.99B
Cash, Cash Equivalents and Short-Term Investments5.00B49.50M49.60M124.90M967.60M1.14B
Total Debt11.32B13.95B5.97B4.09B3.70B2.29B
Total Liabilities15.02B20.86B9.58B7.01B5.71B3.60B
Stockholders Equity8.00B8.16B7.89B7.60B4.83B4.39B
Cash Flow
Free Cash Flow-4.17B-8.93B-1.22B-3.32B-1.34B-1.69B
Operating Cash Flow-2.46B-3.37B1.96B-291.50M-303.50M14.10M
Investing Cash Flow-1.13B-4.14B-3.17B-2.16B-944.60M-1.46B
Financing Cash Flow4.66B7.51B1.13B2.37B1.00B1.88B

Neogen Chemicals Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1156.90
Price Trends
50DMA
1469.02
Positive
100DMA
1355.80
Positive
200DMA
1376.18
Positive
Market Momentum
MACD
58.06
Positive
RSI
48.38
Neutral
STOCH
19.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEOGEN, the sentiment is Neutral. The current price of 1156.9 is below the 20-day moving average (MA) of 1667.97, below the 50-day MA of 1469.02, and below the 200-day MA of 1376.18, indicating a neutral trend. The MACD of 58.06 indicates Positive momentum. The RSI at 48.38 is Neutral, neither overbought nor oversold. The STOCH value of 19.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NEOGEN.

Neogen Chemicals Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
₹40.33B26.920.05%14.60%16.21%
69
Neutral
₹90.88B34.710.62%-2.29%-3.26%
66
Neutral
₹59.22B18.920.97%2.00%7.14%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
55
Neutral
₹43.99B46.140.29%-8.04%-41.66%
53
Neutral
₹29.06B51.390.07%32.18%636.02%
52
Neutral
₹44.88B102.020.09%10.86%-17.60%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:NEOGEN
Neogen Chemicals Ltd.
1,701.20
137.15
8.77%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,777.00
26.45
1.51%
IN:BALAMINES
Balaji Amines Limited
1,827.85
395.86
27.64%
IN:LXCHEM
Laxmi Organic Industries Ltd.
158.70
-30.52
-16.13%
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,242.45
276.81
28.67%
IN:VISHNU
Vishnu Chemicals Limited
599.05
104.81
21.21%

Neogen Chemicals Ltd. Corporate Events

Neogen Chemicals holds virtual EGM to clear equity issue and address investor queries
Mar 29, 2026
Neogen Chemicals Ltd. held an Extraordinary General Meeting on March 29, 2026, via video conferencing and other audio-visual means, in compliance with Ministry of Corporate Affairs and SEBI guidelines for electronic shareholder participation. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 21, 2026